DNLI
Price
$12.80
Change
-$0.94 (-6.84%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
2B
40 days until earnings call
RARE
Price
$35.13
Change
-$0.24 (-0.68%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
3.3B
28 days until earnings call
Ad is loading...

DNLI vs RARE

Header iconDNLI vs RARE Comparison
Open Charts DNLI vs RAREBanner chart's image
Denali Therapeutics
Price$12.80
Change-$0.94 (-6.84%)
Volume$20.81K
Capitalization2B
Ultragenyx Pharmaceutical
Price$35.13
Change-$0.24 (-0.68%)
Volume$12.94K
Capitalization3.3B
DNLI vs RARE Comparison Chart
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. RARE commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and RARE is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (DNLI: $13.74 vs. RARE: $35.37)
Brand notoriety: DNLI and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 298% vs. RARE: 80%
Market capitalization -- DNLI: $1.86B vs. RARE: $3.3B
DNLI [@Biotechnology] is valued at $1.86B. RARE’s [@Biotechnology] market capitalization is $3.3B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, both DNLI and RARE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 5 TA indicator(s) are bullish while RARE’s TA Score has 4 bullish TA indicator(s).

  • DNLI’s TA Score: 5 bullish, 3 bearish.
  • RARE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than RARE.

Price Growth

DNLI (@Biotechnology) experienced а -0.51% price change this week, while RARE (@Biotechnology) price change was -6.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.57%. For the same industry, the average monthly price growth was -10.69%, and the average quarterly price growth was -14.76%.

Reported Earning Dates

DNLI is expected to report earnings on May 13, 2025.

RARE is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (-8.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RARE($3.3B) has a higher market cap than DNLI($2B). RARE YTD gains are higher at: -15.926 vs. DNLI (-32.581). RARE (-469M) and DNLI (-492.89M) have comparable annual earnings (EBITDA) . DNLI has more cash in the bank: 832M vs. RARE (610M). RARE has less debt than DNLI: RARE (40.3M) vs DNLI (48.7M). RARE has higher revenues than DNLI: RARE (560M) vs DNLI (0).
DNLIRAREDNLI / RARE
Capitalization2B3.3B60%
EBITDA-492.89M-469M105%
Gain YTD-32.581-15.926205%
P/E RatioN/AN/A-
Revenue0560M-
Total Cash832M610M136%
Total Debt48.7M40.3M121%
FUNDAMENTALS RATINGS
DNLI vs RARE: Fundamental Ratings
DNLI
RARE
OUTLOOK RATING
1..100
7555
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
73
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
95100
PRICE GROWTH RATING
1..100
9387
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RARE's Valuation (73) in the Biotechnology industry is in the same range as DNLI (94). This means that RARE’s stock grew similarly to DNLI’s over the last 12 months.

RARE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DNLI (100). This means that RARE’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (95) in the Biotechnology industry is in the same range as RARE (100). This means that DNLI’s stock grew similarly to RARE’s over the last 12 months.

RARE's Price Growth Rating (87) in the Biotechnology industry is in the same range as DNLI (93). This means that RARE’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (98) in the Biotechnology industry is in the same range as RARE (100). This means that DNLI’s stock grew similarly to RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIRARE
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
72%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
79%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 7 days ago
79%
Bullish Trend 11 days ago
79%
Declines
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Ad is loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BRWJX23.020.22
+0.96%
MFS Blended Research Growth Eq I
AWSHX61.920.27
+0.44%
American Funds Washington Mutual A
ABCCX11.890.04
+0.34%
American Beacon Balanced C
SAGCX30.44N/A
N/A
ClearBridge Growth C
HMVSX16.83N/A
N/A
Hartford MidCap Value R4